Nelly Kamgaing
Yaounde, CE, Cameroon
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Low Rates of Virologic Failure and Acquired HIV-1 Drug Resistance Among Children in Cameroon: Evidence Following Transition to Dolutegravir-based Regimens in Pediatrics.
Journal: The Pediatric infectious disease journal
Published: January 07, 2026
Interest in long-acting injectable ART among adolescents with perinatally acquired HIV in Cameroon: Implications for implementation in developing countries.
Journal: PLOS global public health
Published: November 25, 2025
Low burden of clinically relevant anaemia and thrombocytopenia among adolescents living with HIV receiving tenofovir/lamivudine plus dolutegravir: the CIPHER-ADOLA study in Cameroon.
Journal: AIDS research and therapy
Published: July 10, 2025
HIV-1 Drug Resistance in Children and Implications for Pediatric Treatment Strategies: A Systematic Review and Meta-analysis.
Journal: Open forum infectious diseases
Published: January 09, 2025
Rates of Viral Non-Suppression and Acquired HIV-1 Drug Resistance Emergence among Children during the Sociopolitical Crisis in the Northwest Region of Cameroon: A Call for Improved Monitoring Strategies.
Journal: Current HIV research
Published: May 11, 2024
Determinants of Immunovirological Response among Children and Adolescents Living with HIV-1 in the Central Region of Cameroon.
Journal: Tropical medicine and infectious disease
Published: January 02, 2024
Determinants of the decision to incision interval in case of emergency caesarean section in Yaoundé' hospitals.
Journal: African health sciences
Published: November 21, 2022
The mother-to-child transmission of HIV-1 and profile of viral reservoirs in pediatric population: A systematic review with meta-analysis of the Cameroonian studies.
Journal: PloS one
Published: November 08, 2021
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
Journal: Antimicrobial resistance and infection control
Published: March 25, 2020
Last Updated: 09/26/2026